Emcitate Is Approved for MCT8 Deficiency, and the Trials Show It Treats the Body but Not the Brain

The first sign is usually a head that will not stay up. A baby who looked fine at birth reaches 3 or 4 months and still cannot hold his head steady, feels loose and floppy when he is picked up, and does not gain weight the way the growth chart says he should. Most pediatricians see that combination and think of a dozen things before they think of the thyroid, and the newborn screening card that every US baby gets does not help, because it measures TSH, and in this disease TSH is normal.

The disease is MCT8 deficiency, also called Allan-Herndon-Dudley syndrome, and in the largest study ever done on it the median age at diagnosis was 24 months. On September 28, 2026, the FDA approved the first drug ever developed for it, Emcitate, making it the first treatment for the disease in the United States.

What MCT8 Deficiency Is and Why Newborn Screening Misses It

Thyroid hormone does 2 jobs. In the body it sets the pace of metabolism, and in the developing brain it directs the growth of nerve cells and the laying down of myelin, the insulation that lets those cells signal quickly. To do the second job it has to get into the brain, and the main door it uses is a transporter protein called MCT8, made by a gene on the X chromosome called SLC16A2.

When that gene is broken, the door is shut. The active hormone, T3, cannot reach the developing brain, and the brain builds itself without the signal it was waiting for. Every child in the natural history study who had a brain MRI showed delayed myelination. At the same time the T3 that cannot get in has nowhere to go, so it accumulates in the blood and pours into tissues that do not depend on MCT8, such as muscle, liver, heart and bone. Those tissues get far too much hormone. Doctors call that state peripheral thyrotoxicosis, and it is why these boys are thin, sweaty, and fast-hearted no matter how much they eat.

The Erasmus Medical Center in Rotterdam, which has become the world's referral center for this condition, published the natural history in 2020 from 151 patients across 47 hospitals in 22 countries. The numbers are hard to read.

The motor and cognitive scores of the boys in that study did not improve with age. Many never walk independently, and speech is limited or absent. A boy who was underweight between ages 1 and 3 had almost 5 times the risk of death of one who was not, which is the first clue that the body half of the disease, the half a drug might reach, is also the half that kills.

The reason diagnosis takes 2 years is the blood test. The standard newborn heel-prick screens for congenital hypothyroidism by measuring TSH, the pituitary signal that rises when the thyroid is underactive. In MCT8 deficiency the thyroid is working, so TSH is normal or only slightly raised and the screen passes. The pattern that gives the diagnosis away is high T3 with low or low-normal T4, and it only shows up if someone orders a full thyroid panel on a floppy baby. In the 2020 study, T3 was above the upper limit in 95% of patients and T4 below the lower limit in 89%. A genetic test of SLC16A2 confirms it.

Tiratricol is not a new molecule. Under the research name Triac, short for triiodothyroacetic acid, it has been known for decades, and a French product called Téatrois was sold for a different thyroid condition long before anyone connected it to this disease. It is a slightly altered form of T3, and the alteration turns out to matter: tiratricol gets into cells through transporters other than MCT8, so it can reach places T3 cannot.

Inside a cell it switches on the same thyroid hormone receptors T3 would. It also signals the pituitary that there is enough hormone around, which lowers TSH and in turn lowers the thyroid's own output. The result that trials have shown over and over is a fall in blood T3 into or near the normal range, which shuts off the thyrotoxicosis in the body. The hope, from mouse studies where tiratricol given in early life normalized brain development, was that it would also feed the brain. That hope is where the evidence gets complicated.

Egetis Therapeutics, a small Swedish company, took the program to the European Medicines Agency and won approval on February 12, 2025. The EU indication is specific: treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency, from birth. Not treatment of MCT8 deficiency, and not treatment of the neurological disease. The wording is a summary of what the trials proved. The European Thyroid Association's 2024 guidelines recommend it as long-term therapy for every patient with the condition, and Germany began dispensing it on May 1, 2025.

What the FDA Approved: Emcitate's US Label

The FDA's approval on September 28, 2026 follows the European wording closely. Emcitate is approved to treat peripheral thyrotoxicosis in adults and children with MCT8 deficiency, and the label adds that it is not recommended for primary hypothyroidism, the ordinary underactive thyroid. It carries a boxed warning, the FDA's most prominent kind, that thyroid hormones including Emcitate must not be used to treat obesity or for weight loss, and it must not be given to anyone with primary hyperthyroidism (FDA, 2026; Emcitate prescribing information, 2026).

Emcitate comes as a 350 microgram scored tablet that is stirred into room-temperature drinking water in a 10 to 12 mL syringe and given by mouth or through a feeding tube, once a day or split into 2 or 3 doses. Children who weigh 10 kg or less start at 175 micrograms a day and everyone else at 350, and the dose goes up by the same step about every 2 weeks until total T3 falls below the middle of the normal range for age. The tablets live in the refrigerator, and when treatment stops the dose is stepped down rather than stopped all at once.

The label also flags interactions worth knowing before the first dose. Other thyroid medicines such as levothyroxine should not be combined with it, iron and calcium supplements should be given at the same time each day relative to Emcitate, acid-reducing proton pump inhibitors can change how much is absorbed, and it can strengthen the effect of warfarin. For children under 8, the label suggests periodic eye checks for lens changes, a precaution based on high-dose studies in dogs.

What the Emcitate Trials Found, Study by Study

The FDA application rests on 3 clinical trials plus real-world follow-up, and they answer 3 different questions. It helps to take them one at a time.

Triac Trial I asked whether the drug lowers T3

The first trial enrolled 46 patients aged 10 months to 66 years at 9 hospitals starting in October 2014, treated everyone with tiratricol, and measured what happened after a year. It was published in The Lancet Diabetes & Endocrinology in 2019. Mean total T3 fell from 4.97 to 1.82 nmol/L, which is a drop from clearly thyrotoxic into the normal range, on a mean dose of 38.3 micrograms per kilogram per day. Heart rate came down, blood pressure came down, and weight improved. Treatment-related side effects, all of them sweating or irritability, occurred in 6 of the 46 patients, and none of the 26 serious adverse events over the year were judged to be caused by the drug.

It was a single-arm trial, which means every patient got the drug and there was no placebo group, so on its own it can show that T3 fell but cannot prove the drug is why. Nobody seriously doubts it, because a hormone analog lowering hormone levels is about as mechanistically plain as pharmacology gets, but it is why the FDA later asked for a randomized study.

Triac Trial II asked whether starting early helps the brain

This is the trial families cared about. Triac Trial II enrolled 22 boys who were under 30 months old when they started, treated them for 96 weeks at higher doses per kilogram than the first trial, and measured motor and cognitive development on 2 standard scales, the GMFM-88 and the Bayley-III. The comparison group was not a placebo arm but historical controls, meaning untreated boys from the natural history data. The bet was that if enough tiratricol reached the brain during the window when thyroid hormone shapes it, these boys would develop differently from the boys who came before them.

On June 19, 2024 Egetis announced that the trial did not meet its co-primary endpoints. There were numerical improvements versus baseline on both scales, but they were not statistically significant against the historical controls. T3 fell in every boy, and the drug was tolerated at the higher doses. The principal investigator, Edward Visser of Erasmus, said the study did not show a clinically relevant improvement on the neurocognitive endpoints, and the company said the result did not change its regulatory plans because the approvals were always going to rest on the thyrotoxicosis data.

That last sentence deserves a closer look than it usually gets. A failed trial that does not change the plan is only possible when the plan never depended on it, and that is the case here: the EMA had agreed in advance that approval would rest on T3 and the body-side effects. The trial that would have made this a brain drug came back negative, and the drug is being approved as a body drug. Both things are true, and a family deciding whether to travel to an expanded access site should hold both.

ReTRIACt asked the FDA's question

The FDA wanted randomized, placebo-controlled evidence, and for a disease this rare the practical design was a withdrawal study. ReTRIACt enrolled 20 male patients aged 5 to 31. The 15 who reached a stable dose were randomly assigned to keep taking tiratricol or to switch to placebo for 30 days, or until their T3 rose above the normal limit and they had to be rescued: 8 to placebo and 7 to continue.

The outcome was clean in one sense and awkward in another. On placebo, mean T3 rose by 64.6 ng/dL in 30 days, while on the drug it was essentially flat, and every patient switched to placebo saw a bigger rise than any of the 7 who stayed on tiratricol, with no overlap between the groups. The rate of T3 change was statistically significant (p=0.034). The awkward part is that the endpoint that hit was added after FDA comments during the review, while the study's original endpoint, the number of patients who needed rescue, was 4 on placebo versus 1 on drug once a dropout was counted, and did not reach significance (p=0.182). Egetis reported all of this in its November 14, 2025 announcement rather than burying it, which counts for something, and a 15-patient study in an ultra-rare disease was never going to carry much statistical weight either way. The company also submitted a real-world comparison of survival in treated versus untreated males from the Erasmus cohort, which it says showed a significant benefit; that analysis has not yet appeared in a peer-reviewed journal.

Why a Body-Only Drug Still Matters in MCT8 Deficiency

It would be easy to read the last section as a letdown, and for families who hoped for a brain treatment it is one. There is a reason the drug is still worth wanting, and it comes back to the natural history data. The boys who died in that study died of pneumonia and sudden death, and the risk factors that predicted death were being underweight and having poor muscle tone, which are the thyrotoxicosis half of the disease. A body burning through calories it cannot replace, a heart racing at rest, and muscles that never get to build are not cosmetic problems in a child who cannot clear his own airway. If tiratricol lets a boy gain weight and slows his heart, the survival argument writes itself, even before the Erasmus analysis is published.

There is a second, quieter reason. Every child in the US who has been on tiratricol until now has been on it through a trial or a compassionate use request, with the supply and the paperwork controlled case by case. The approval turns that into a prescription.

Emcitate Side Effects and What Gets Monitored

The US label lists diarrhea, vomiting, rash and excessive sweating as the most common side effects. In Triac Trial I, 13% of the 46 patients had diarrhea, 11% vomiting, 9% rash and 7% sweating, and in the 20-patient withdrawal study vomiting and rash each affected 2 patients (Emcitate prescribing information, 2026). Most of what goes wrong is what too much thyroid hormone feels like: while the dose was being raised in Triac Trial I, heart rate rose for a while in 35% of patients and blood pressure in 26%, and 30% had at least 1 side effect of that kind, such as diarrhea, sweating, irritability, trouble sleeping or nightmares. The EU product information lists a similar set, and in Triac Trial I the drug did not cause any of the serious events.

The practical risk is overshooting. The dose is not simply set by weight; it starts low and is raised every 2 weeks against blood T3 until T3 sits in the target range, and it stays there only if the blood tests continue, now with the specialized LC-MS/MS method described above. A child on tiratricol will have more blood draws in the first months than most families expect, and that is the safety system working. The EU label rules out use in pregnancy, while the US label notes there are no pregnancy data and does not forbid it. The Emcitate drug page carries the full US label details.

How to Get Emcitate in the US After the September 28th Approval

Egetis expects Emcitate to be commercially available in the United States 8 to 10 weeks after the approval, and it has set up a patient support program called Egetis RareLink with the specialty pharmacy PANTHERx Rare to handle access, education and delivery (1-844-434-3847). The gap between an approval and a first dose is usually longer than families expect, so the steps below still matter.

Get the genetic result in hand

Expanded access required a diagnosis of MCT8 deficiency confirmed by genetic testing of SLC16A2, and it is the most direct proof of the diagnosis the new label covers. If your child was diagnosed on thyroid blood work alone, ask for the gene test now.

If your child is on expanded access, plan the switch

Before approval, Egetis, through its subsidiary Rare Thyroid Therapeutics, ran an expanded access program listed on ClinicalTrials.gov as NCT05911399 at 17 hospitals in 15 states. If your child is treated there, ask the site how and when patients move to commercial supply so there is no gap between the two, and call Egetis RareLink at 1-844-434-3847 to start the insurance paperwork early.

Ask for a pediatric endocrinologist who has treated it

Most endocrinologists have never seen a case. The MCT8-AHDS Foundation, a parent-run group, keeps a list of physicians with experience of the condition and can point you to the nearest expanded access site.

If you are pregnant with an affected boy

A physician-sponsored expanded access protocol at the University of Miami (NCT04143295) treats affected male fetuses before birth in families with a known SLC16A2 variant. It is the only effort anywhere to reach the brain during the window the trials could not, and it exists because Triac Trial II suggested that 30 months is already too late.

After an approval, expect prior authorization

A first-in-disease orphan drug with no US price history will be reviewed case by case by insurers. Keep the natural history numbers, the thyroid panel, and the genetic report together in one folder; that is what an appeal letter is built from.

One more thing sits behind the approval. The FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher with it, which the company can sell to another drugmaker and says it may sell in the 4th quarter of 2026; vouchers like it have sold for $150 million and up. For a company whose revenue until now came from one drug in Europe, that voucher is a large part of why the US filing happened as quickly as it did. That is not a criticism, just an explanation of the calendar.